PSMC2/CCND1 axis promotes development of ovarian cancer through regulating cell growth, apoptosis and migration

被引:0
|
作者
Dawei Zhu
Jie Huang
Ning Liu
Wei Li
Limei Yan
机构
[1] Daping Hospital,Department of Gynaecology and Obstetrics
[2] Army Medical University,Department of Obstetrics and Gynaecology
[3] Shengjing Hospital of China Medical University,undefined
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Ovarian cancer is known as one of the most common malignancies of the gynecological system, whose treatment is still not satisfactory because of the unclear understanding of molecular mechanism. PSMC2 is an essential component of 19 S regulatory granules in 26 S proteasome and its relationship with ovarian cancer is still not clear. In this study, we found that PSMC2 was upregulated in ovarian cancer tissues, associated with tumor grade and could probably predict poor prognosis. Knocking down the endogenous PSMC2 expression in ovarian cancer cells could decrease colony formation ability, cell motility and cell proliferation rate, along with increasing cell apoptosis rate. Cells models or xenografts formed by cells with relatively lower expression of PSMC2 exhibited weaker oncogenicity and slower growth rate in vivo. Moreover, gene microarray was used to analyze the alteration of gene expression profiling of ovarian cancer induced by PSMC2 knockdown and identify CCND1 as a potential downstream of PSMC2. Further study revealed the mutual regulation between PSMC2 and CCND1, and demonstrated that knockdown of CCND1 could enhance the regulatory effects induced by PSMC2 knockdown and overexpression of CCND1 reverses it. In summary, PSMC2 may promote the development of ovarian cancer through CCND1, which may predict poor prognosis of ovarian cancer patients.
引用
收藏
相关论文
共 50 条
  • [21] JARID2 inhibits leukemia cell proliferation by regulating CCND1 expression
    Su, Chang-Liang
    Deng, Tao-Ran
    Shang, Zhen
    Xiao, Yi
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2015, 102 (01) : 76 - 85
  • [22] JARID2 inhibits leukemia cell proliferation by regulating CCND1 expression
    Chang-Liang Su
    Tao-Ran Deng
    Zhen Shang
    Yi Xiao
    International Journal of Hematology, 2015, 102 : 76 - 85
  • [23] Circ-RNF111 Promotes Proliferation of Ovarian Cancer Cell SKOV-3 by Targeting the MiR-556-5p/CCND1 Axis
    Zuo, Li
    Tan, Yue
    Xu, Qiao-ling
    Li, Xiao-li
    Xiao, Mi
    BIOCHEMICAL GENETICS, 2024, 62 (06) : 4884 - 4895
  • [24] Dlx5 promotes cancer progression through regulation of CCND1 in oral squamous cell carcinoma (OSCC)
    Zhang, Jianfei
    Wu, Jinyang
    Chen, Yang
    Zhang, Wenbin
    BIOCHEMISTRY AND CELL BIOLOGY, 2021, 99 (04) : 424 - 434
  • [25] SNAI2 promotes the development of ovarian cancer through regulating ferroptosis
    Jin, Yunfeng
    Chen, Li
    Li, Li
    Huang, Guoqin
    Huang, Hua
    Tang, Chunhui
    BIOENGINEERED, 2022, 13 (03) : 6451 - 6463
  • [26] Lower miR-630 expression predicts poor prognosis of osteosarcoma and promotes cell proliferation, migration and invasion by targeting PSMC2
    Li, G-W
    Yan, X.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2019, 23 (05) : 1915 - 1925
  • [27] High expression of PSMC2 promotes gallbladder cancer through regulation of GNG4 and predicts poor prognosis
    Zhu, Dawei
    Gu, Xing
    Lin, Zhengyu
    Yu, Dandan
    Wang, Jing
    ONCOGENESIS, 2021, 10 (05)
  • [28] The function and mechanism of the JARID2/CCND1 axis in modulating glioma cell growth and sensitivity to temozolomide (TMZ)
    Kuang, Weilu
    Jiang, Wuzhong
    Chen, Yinyun
    Tian, Yifu
    Liu, Zhengzheng
    CANCER BIOLOGY & THERAPY, 2021, 22 (5-6) : 392 - 403
  • [29] LncRNA HOTAIR Regulates CCND1 and CCND2 Expression by Sponging miR-206 in Ovarian Cancer
    Chang, Lei
    Guo, Ruixia
    Yuan, Zhongfu
    Shi, Huirong
    Zhang, Dongya
    CELLULAR PHYSIOLOGY AND BIOCHEMISTRY, 2018, 49 (04) : 1289 - 1303
  • [30] Circ-PITX1 Promotes the Progression of Non-Small Cell Lung Cancer Through Regulating the miR-1248/CCND2 Axis
    Yue, Qianyu
    Xu, Yanyan
    Deng, Xiaoli
    Wang, Shenglan
    Qiu, Jingman
    Qian, Baojiang
    Zhang, Yunhui
    ONCOTARGETS AND THERAPY, 2021, 14 : 1807 - 1819